Researchers have unveiled a potential breakthrough in the treatment of pancreatic cancer, the world’s deadliest form of the disease. According to a report by The Guardian, a new daily pill called daraxonrasib has successfully doubled the survival time for patients with advanced cases of the cancer.
The findings, presented at the American Society of Clinical Oncology’s (Asco) annual meeting in Chicago, represent a significant shift in a field that has seen few advancements in decades. In a trial involving 500 patients, those treated with the drug lived for an average of 13.2 months, compared with 6.6 to 6.7 months for those receiving standard chemotherapy.
Experts at the conference described the results as a "gamechanger." Dr. Julie Gralow, Asco’s chief medical officer, went further, stating, "I’ve heard this study described as a home run. I would actually say it’s a grand slam."
Targeting the 'Holy Grail'
The drug functions by targeting the Kras protein, which acts as an early driver for almost all pancreatic cancers. By binding to and shutting down this protein, daraxonrasib prevents cancer cells from receiving the signals required to grow and divide. Because more than 90% of patients with the most common form of the disease possess a mutation in the Kras gene, the drug offers a broad application for those previously facing limited options.
Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, noted the emotional impact of the data, which was led by researchers at the Dana-Farber Cancer Institute. "Having treated pancreatic cancer for 16 years, I actually started crying in clinic," Dr. Shroff said. "This is such an incredibly impactful study for our patients."
Beyond the survival gains, the trial reported that daraxonrasib produced fewer side effects than current chemotherapy protocols. Advocates for patients, including Paula Hanford of Pancreatic Cancer Action, highlighted that the discovery provides "real hope" for families. However, health officials emphasized that the next challenge lies in ensuring rapid access to the medication, as the disease progresses quickly; half of all patients currently die within three months of diagnosis.
